Athira Pharma (ATHA) Competitors

$10.33 +0.26 (+2.58%)

As of 05/22/2026

ATHA vs. MENS, PLYX, PLX, HURA, and CRDL

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Jyong Biotech (MENS), Polaryx Therapeutics (PLYX), Protalix BioTherapeutics (PLX), TuHURA Biosciences (HURA), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Athira Pharma (NASDAQ:ATHA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	N/A	N/A	N/A
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A

Jyong Biotech's return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Athira Pharma	N/A	-107.06%	-89.89%

In the previous week, Jyong Biotech and Jyong Biotech both had 1 articles in the media. Jyong Biotech's average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

57.1% of Athira Pharma shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Athira Pharma has a consensus target price of $4.00, indicating a potential downside of 61.28%. Given Athira Pharma's higher possible upside, analysts clearly believe Athira Pharma is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Athira Pharma beats Jyong Biotech on 3 of the 5 factors compared between the two stocks.

How does Athira Pharma compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Athira Pharma (NASDAQ:ATHA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Polaryx Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 177.78%. Athira Pharma has a consensus price target of $4.00, indicating a potential downside of 61.28%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Athira Pharma had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 1 mentions for Athira Pharma and 0 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.69 beat Athira Pharma's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Positive
Athira Pharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A

Polaryx Therapeutics' return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Athira Pharma	N/A	-107.06%	-89.89%

57.1% of Athira Pharma shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Polaryx Therapeutics beats Athira Pharma on 6 of the 9 factors compared between the two stocks.

How does Athira Pharma compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 19.8% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.22	$8.31M	$0.18	11.67
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A

Protalix BioTherapeutics presently has a consensus target price of $12.00, indicating a potential upside of 471.43%. Athira Pharma has a consensus target price of $4.00, indicating a potential downside of 61.28%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Athira Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Athira Pharma	N/A	-107.06%	-89.89%

In the previous week, Protalix BioTherapeutics had 5 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Protalix BioTherapeutics and 1 mentions for Athira Pharma. Protalix BioTherapeutics' average media sentiment score of 0.80 beat Athira Pharma's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market.

Summary

Protalix BioTherapeutics beats Athira Pharma on 10 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to TuHURA Biosciences?

Athira Pharma (NASDAQ:ATHA) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Athira Pharma's return on equity of -107.06% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
TuHURA Biosciences	N/A	-156.12%	-105.38%

In the previous week, TuHURA Biosciences had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for TuHURA Biosciences and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 equaled TuHURA Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Athira Pharma presently has a consensus target price of $4.00, suggesting a potential downside of 61.28%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 260.00%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Athira Pharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 19.8% of Athira Pharma shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Summary

Athira Pharma and TuHURA Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Athira Pharma's return on equity of -107.06% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Athira Pharma	N/A	-107.06%	-89.89%

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A

Cardiol Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 543.94%. Athira Pharma has a consensus target price of $4.00, indicating a potential downside of 61.28%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.03 beat Athira Pharma's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.79, meaning that its share price is 179% more volatile than the broader market.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cardiol Therapeutics and Athira Pharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHA vs. The Competition

Export

Metric	Athira Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.74M	$3.38B	$6.41B	$12.31B
Dividend Yield	N/A	2.28%	2.76%	5.31%
P/E Ratio	-1.07	18.93	21.01	25.66
Price / Sales	N/A	327.88	555.71	83.69
Price / Cash	N/A	131.89	44.57	56.72
Price / Book	0.89	7.11	10.37	7.14
Net Income	-$96.94M	$24.45M	$3.56B	$335.72M
7 Day Performance	-8.26%	3.32%	5.10%	3.03%
1 Month Performance	12.77%	2.13%	3.58%	2.88%
1 Year Performance	274.28%	63.43%	34.18%	35.20%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHA Athira Pharma	0.7183 of 5 stars	$10.33 +2.6%	$4.00 -61.3%	+272.3%	$40.74M	N/A	N/A	40	News Coverage Gap Up
MENS Jyong Biotech	N/A	$2.09 +1.0%	N/A	N/A	$157.38M	N/A	N/A	31	Earnings Report
PLYX Polaryx Therapeutics	N/A	$3.28 -3.2%	$10.00 +204.9%	N/A	$154.26M	N/A	N/A	11	Earnings Report
PLX Protalix BioTherapeutics	3.5116 of 5 stars	$1.91 -1.5%	$12.00 +528.3%	+27.3%	$153.89M	$52.74M	N/A	200	Analyst Revision
HURA TuHURA Biosciences	2.2092 of 5 stars	$2.42 +0.8%	$9.00 +271.9%	-16.9%	$152.84M	N/A	N/A	N/A	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHA) was last updated on 5/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (ATHA) Competitors

ATHA vs. MENS, PLYX, PLX, HURA, and CRDL

How does Athira Pharma compare to Jyong Biotech?

Summary

How does Athira Pharma compare to Polaryx Therapeutics?

Summary

How does Athira Pharma compare to Protalix BioTherapeutics?

Summary

How does Athira Pharma compare to TuHURA Biosciences?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (ATHA) Competitors

ATHA vs. MENS, PLYX, PLX, HURA, and CRDL

How does Athira Pharma compare to Jyong Biotech?

Which has better valuation & earnings, MENS or ATHA?

Is MENS or ATHA more profitable?

Does the media favor MENS or ATHA?

Do institutionals & insiders believe in MENS or ATHA?

Do analysts rate MENS or ATHA?

Summary

How does Athira Pharma compare to Polaryx Therapeutics?

Do analysts prefer PLYX or ATHA?

Does the media prefer PLYX or ATHA?

Which has better earnings & valuation, PLYX or ATHA?

Is PLYX or ATHA more profitable?

Do institutionals and insiders believe in PLYX or ATHA?

Summary

How does Athira Pharma compare to Protalix BioTherapeutics?

Do insiders and institutionals believe in PLX or ATHA?

Which has preferable valuation & earnings, PLX or ATHA?

Do analysts prefer PLX or ATHA?

Is PLX or ATHA more profitable?

Does the media prefer PLX or ATHA?

Which has more risk & volatility, PLX or ATHA?

Summary

How does Athira Pharma compare to TuHURA Biosciences?

Is ATHA or HURA more profitable?

Does the media refer more to ATHA or HURA?

Do analysts prefer ATHA or HURA?

Which has more risk and volatility, ATHA or HURA?

Do insiders & institutionals hold more shares of ATHA or HURA?

Which has higher earnings and valuation, ATHA or HURA?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Is CRDL or ATHA more profitable?

Which has better valuation and earnings, CRDL or ATHA?

Do analysts prefer CRDL or ATHA?

Does the media favor CRDL or ATHA?

Which has more volatility and risk, CRDL or ATHA?

Do institutionals and insiders believe in CRDL or ATHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools